Trial Profile
Phase II Single-arm Study of the Combination of Palbociclib and Cetuximab in KRAS/NRAS/BRAF Wild-type Metastatic Colorectal Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 07 Feb 2024
Price :
$35
*
At a glance
- Drugs Cetuximab (Primary) ; Palbociclib (Primary)
- Indications Colon cancer; Colorectal cancer
- Focus Therapeutic Use
- 30 Jan 2023 Planned End Date changed from 13 Jan 2026 to 26 Jan 2026.
- 30 Jan 2023 Planned primary completion date changed from 13 Jan 2023 to 26 Jan 2026.
- 30 Jan 2023 Status changed from recruiting to active, no longer recruiting.